Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc. engages in the research, development, manufacturing, marketing, and sale of prescription pharmaceutical products in the United States. Its products include Brisdelle, a non-hormonal therapy for vasomotor symptoms associated with menopause; Minivelle, an estrogen therapy patch for the treatment of vasomotor symptoms due to menopause and prevention of post-menopausal osteoporosis; CombiPatch, an estradiol/norethindrone acetate transdermal system to treat symptoms of hot flashes, and vaginal dryness associated with menopause; Daytrana, a transdermal medication to treat the symptoms of ADHD in children 6 to 17 years old; and Pexeva to treat major depressive disorder, generalized anxiety disorder, panic disorder, or obsessive compulsive disorder. Its products are used for the treatment of women’s health, as well as central nervous system disorders, including attention deficit hyperactivity disorder (ADHD). The company was founded in 1987 and is based in Miami, Florida with an additional office in Jersey City, New Jersey. As of August 26, 2009, Noven Pharmaceuticals, Inc. operates as a subsidiary of Hisamitsu Pharmaceutical Co., Inc.